No headlines found.
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
Business Wire (Tue, 31-Mar 4:05 PM ET)
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
Business Wire (Tue, 24-Mar 8:00 AM ET)
Business Wire (Tue, 17-Feb 8:00 AM ET)
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
Business Wire (Mon, 9-Feb 8:00 AM ET)
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
Turn Therapeutics trades on the NASDAQ stock market under the symbol TTRX.
As of April 28, 2026, TTRX stock price declined to $3.60 with 2,774 million shares trading.
TTRX has a beta of 0.17, meaning it tends to be less sensitive to market movements. TTRX has a correlation of 0.00 to the broad based SPY ETF.
TTRX has a market cap of $106.00 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that TTRX belongs to (by Net Assets): VTI.
TTRX support price is $3.48 and resistance is $3.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TTRX shares will trade within this expected range on the day.
